Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes

By Postma Maarten J   Kruidhof Hanneke   Berg Lolkje TW de Jong-van den   Zeeuw Dick de  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 9, 2003-09 ,pp. : 1543-1550

Informa Healthcare

Access to resources Recommend Favorite

The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

By Carides George W.  

PharmacoEconomics, Vol. 24, Iss. 6, 2006-01 ,pp. : 549-558

Adis International

Access to resources Recommend Favorite

Optimisation of the Management of Patients with Coronary Heart Disease and Type 2 Diabetes Mellitus

By Wilson S.H.   Kennedy F.P.   Garratt K.N.  

Drugs & Aging, Vol. 18, Iss. 5, 2001-01 ,pp. : 325-333

Adis International

Access to resources Recommend Favorite

Preventing Macrovascular Disease in Patients with Type 2 Diabetes Mellitus

By Johansen O.E.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 4, 2003-01 ,pp. : 283-297

Adis International

Access to resources Recommend Favorite

Muraglitazar: multiple benefits in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1496, 2005-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite